Print Page   |   Contact Us   |   Sign In   |   Become a Member
Site Search
News from the Field
Blog Home All Blogs
Search all posts for:   

 

View all (22) posts »
 

February News Roundup

Posted By Connections Editor , Friday, February 28, 2014
Updated: Tuesday, February 18, 2014

bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia

bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.

BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia.

Independent Data Monitoring Committee recommends Phase III study of IMBRUVICA™ (ibrutinib) versus ofatumumab be stopped early based on statistically significant improvement in progression free survival and overall survival

Pharmacyclics, Inc. announced that an Independent Data Monitoring Committee (IDMC) unanimously recommended that the Phase III RESONATE study, PCYC-1112-CA, a head-to-head comparison of IMBRUVICATM (ibrutinib) versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met.

University of Utah doctor performs historic first procedure using new technique of retrograde gene therapy on a human heart

Ernie Lively became the first patient in the world to undergo retrograde gene therapy at University of Utah Hospital, a novel procedure designed to deliver stem cells to the heart to repair damaged muscle and arteries in the most minimally invasive way possible.

NASA, CASIS Make Space Station Accessible for Stem Cell Research

NASA and the Center for the Advancement of Science in Space (CASIS) are enabling research aboard the International Space Station that could lead to new stem cell-based therapies for medical conditions faced on Earth and in space. Scientists will take advantage of the space station's microgravity environment to study the properties of non-embryonic stem cells.

apceth’s Ground-Breaking First-In-Man, First-In-Class Clinical Trial in Oncology with Genetically Modified Mesenchymal Stromal Cells Is Now Enrolling

As a world first, apceth announced that the TREAT ME Phase I/II clinical trial for patients suffering from advanced adenocarcinoma of the gastro-intestinal tract has commenced. This is the first clinical trial world-wide with genetically-modified mesenchymal stromal cells.

New Report on Stem Cell Research Reveals the Field is Growing Twice as Fast as the World Average

Elsevier, EuroStemCell, and Kyoto University's Institute for Integrated Cell-Material Sciences, released "Stem CellResearch report: Trends and Perspectives on the Evolving International Landscape" at the World Stem Cell Summit. This new, comprehensive analysis of the growth and development of the stem cell field as a whole, closely examines the research landscape for embryonic stem cell, human embryonic stem cell and induced pluripotent stem cell.

Child with Cerebral Palsy Treated with Umbilical Cord Blood Derived Autologous Stem Cells

Cryo-Save Group N.V., the leading international stem cell storage company and the largest family stem cell bank in Europe, announced that on December 10th 2013 a 4-year-old girl in Spain received an infusion of stem cells derived from her own umbilical cord blood for the treatment of her cerebral palsy.

 



 

This post has not been tagged.

Share |
Permalink | Comments (0)
 
Association Management Software Powered by YourMembership.com®  ::  Legal